A new trading day began on Friday, with Rocket Pharmaceuticals Inc (NASDAQ: RCKT) stock price down -7.44% from the previous day of trading, before settling in for the closing price of $3.09. RCKT’s price has ranged from $2.19 to $22.01 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -11.60% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 23.11%. With a float of $99.22 million, this company’s outstanding shares have now reached $107.88 million.
In an organization with 299 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Rocket Pharmaceuticals Inc (RCKT) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Rocket Pharmaceuticals Inc is 8.05%, while institutional ownership is 86.91%. The most recent insider transaction that took place on Jul 03 ’25, was worth 4,257. In this transaction Chief Financial Officer of this company sold 1,477 shares at a rate of $2.88, taking the stock ownership to the 128,173 shares. Before that another transaction happened on Jul 03 ’25, when Company’s Officer proposed sale 1,477 for $2.88, making the entire transaction worth $4,256.
Rocket Pharmaceuticals Inc (RCKT) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.71 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.46 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.76% during the next five years compared to -11.60% drop over the previous five years of trading.
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Trading Performance Indicators
Here are Rocket Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.50, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -1.48 in one year’s time.
